No Data
No Data
Sealand Securities initiated the first "buy" rating for Sisram Medical Technology (01696), indicating that performance recovery is expected and the current position is cost-effective.
Sealand Securities released a research report stating that the upstream of the medical beauty industry consists of raw material and medical device manufacturers, with high entry barriers and gross margins ranging from 80% to 95%; the middle stream consists of dealers and medical beauty institutions, with a scattered market structure and lower profits; the downstream consists of customer acquisition platforms, with gross margins of approximately 60% to 80%. The medical beauty industry combines both "medical" and "consumer" attributes and has the characteristics of high investment, high output, and high risk in the medical industry. At the same time, it is also an optional consumer behavior influenced by factors such as per capita disposable income and subjective willingness. The report pointed out that Sisram Med (01696) is the leader in the medical beauty industry, with energy-based medical beauty, injection filling, and...
Sisram Med [01696] is now trading at HKD 3.53, with a rise of 10.66%.
As of 09:35, Sisram Med [01696] reported a price of HKD 3.53, up HKD 0.34 or 10.66% from the previous closing price of HKD 3.19. The trading volume was 0.6276 million HKD. The highest price today was HKD 3.53, and the lowest price was HKD 3.31. Based on the previous closing price, the 10-day average price was HKD 4.19, and the 50-day average price was HKD 3.76. The PE ratio is currently 7.41 times, and the 14-day strength index is 48.10.
Express News | Sirsram Medical Announces Nmpa Approval for Daxxify
Sirsram Medical Announces NMPA Approval for DAXXIFY
Sisram Med: The world's first patented long-acting type A botulinum toxin Daxifei has officially obtained approval for listing in China.
Hong Kong, September 9, 2024 / PRNewswire / - Sisram Medical Technology Co., Ltd. (referred to as "Sisram" in English, stock code: 1696.HK), together with its subsidiaries collectively referred to as "the Group", announced today that its trademarked revolutionary long-acting type A botulinum toxin product under the brand name Daxify (in English, DAXXIFY) (project code RT002) has officially obtained approval from the National Medical Products Administration of China for its registration application. This product is used for temporary improvement in adults.
Sisram Med (01696.HK): Injection type A botulinum toxin product Daxifei approved in China.
On September 9, Sisram Medical Technology (01696.HK) announced that it has been authorized by Fosun Pharma Industry Development Co., Ltd. in Shanghai (hereinafter referred to as "Fosun Pharma Industry") to market the injectable type A botulinum toxin, DaxibotulinumtoxinA-lanm (operating under the Chinese trademark Daxif). The drug, with the English trademark DAXXIFY and project code RT002, is used for the temporary improvement of moderate to severe glabellar lines caused by the activity of the corrugator and/or procerus muscles in adults. The pharmaceutical registration application for this product has recently been approved by the National Medical Products Administration.
No Data
No Data